TrialOncology2018

A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.

Melanie B Thomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.